Ryman rights trading ends on a sour note

Ryman rights trading ends on a sour note
Salt Funds' Matt Goodson said time will tell whether Ryman shares are cheap. (Image: Salt Funds)
Jenny Ruth
Ryman Healthcare’s $902 million rights issue is drawing to a dismal close, with the price of the rights falling as low as 7.5 cents on Tuesday, the last day of trading.Two weeks ago, in the institutional book-build auction process, institutional investors were prepared to pay an effective $1 for the rights.You could say that was a little disappointing because the theoretical value of the rights price was $1.03 – institutions paid $6 for the shares issued at $5, so the additional price paid reflected the value they put on the rights....

More Finance

The invisible chair: Wayne Boyd
Finance

The invisible chair: Wayne Boyd

One of NZ's best, lowest-profile directors reflects on a career in governance.

Pattrick Smellie 03 Dec 2024
BlackRock insists: 'We’re committed to NZ'
Finance

BlackRock insists: 'We’re committed to NZ'

But BlackRock cannot say whether its proposed $2b NZ climate fund will be established.

Pattrick Smellie 29 Nov 2024
Banks launch confirmation of payee
Finance

Banks launch confirmation of payee

Mismatched account payee details will be red-flagged to help reduce scams.

Maria Slade 29 Nov 2024
Major corporates disavowing Du Val information memorandum
Finance

Major corporates disavowing Du Val information memorandum

Corporates disavow Du Val IM amid regulatory scrutiny.

Garth Bray 27 Nov 2024